First Solar (FSLR) Q1 2026 Earnings Transcript

First Solar reported record Q1 net sales of $1.0 billion, up 24% year over year, with gross margin expanding to 47%, adjusted EBITDA of $520 million, and diluted EPS of $3.22. Management left full-year 2026 guidance unchanged and guided Q2 adjusted EBITDA to $400 million-$500 million, while noting lower international utilization and more underutilization charges in Malaysia and Vietnam. The call also highlighted progress on CURE technology, a 47.9 GW backlog worth $14.4 billion, and continued dependence on Section 232 and other trade-policy outcomes for bookings and Southeast Asian capacity decisions.

Analysis

The setup is less about a clean earnings beat and more about a widening policy moat that is converting into pricing power. The key second-order effect is that management is deliberately throttling optionality in Southeast Asia while building more domestic finishing and content capture in the U.S.; that shifts value from low-margin assembly toward higher-margin, policy-protected downstream steps. In practice, this makes the business less cyclical than the market assumes because the most important volumes are now tied to contract backlogs extending multiple years, not spot module economics.

The market is likely underestimating how much of the near-term EBITDA is being held back intentionally. Q2 looks like a temporary trough in utilization and mix, but that should be viewed as a setup for a stronger 2H if trade decisions land in management’s favor or if backlog conversion accelerates after policy clarity. The real catalyst is not just a tariff ruling; it is the unlocking of deferred bookings, which could re-rate the forward order book and reduce the discount investors apply to outer-year earnings.

The contrarian risk is that the stock may already be pricing a best-case policy outcome while ignoring execution friction. If trade clarity slips, the company will be forced to absorb higher underutilization costs and potentially leave international capacity stranded longer than expected, which would compress margins even with strong demand. A more subtle risk is that the new technology narrative becomes a timing mismatch: investors may capitalize CURE and perovskite optionality too early while the cash flows from those programs remain back-end loaded over 2027-2028.

Key Decisions for Investors

• Long FSLR into the next 2-6 weeks as a policy-event trade, but size modestly; upside is a re-rating on tariff clarity and deferred booking release, while downside is a timing miss that likely compresses the multiple by 10-15%.
• Pair long FSLR / short ENPH or a broad solar hardware basket for 1-3 months: FSLR has a policy-protected domestic moat and visible backlog, while more exposed peers remain trapped in pricing pressure and weaker channel demand.
• Buy FSLR Jan-2027 calls or call spreads to express the CURE/perovskite optionality; this captures 2027-2028 technology-adjuster upside without paying full equity beta for the near-term policy uncertainty.
• If already long, hedge into any sharp post-232 rally by selling near-dated covered calls; the stock’s near-term upside likely comes in bursts around policy headlines, while execution risk remains elevated in the intervening quarters.